Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Short Interest Update

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,880,000 shares, a decline of 18.6% from the January 15th total of 2,310,000 shares. Approximately 8.0% of the company’s shares are short sold. Based on an average daily volume of 352,500 shares, the days-to-cover ratio is currently 5.3 days.

Lexeo Therapeutics Stock Performance

Shares of LXEO opened at $4.50 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. Lexeo Therapeutics has a twelve month low of $3.84 and a twelve month high of $19.50. The firm’s 50 day moving average price is $6.04 and its two-hundred day moving average price is $8.30. The firm has a market cap of $148.82 million, a P/E ratio of -1.42 and a beta of 2.99.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Northern Trust Corp lifted its stake in Lexeo Therapeutics by 7.1% in the fourth quarter. Northern Trust Corp now owns 214,284 shares of the company’s stock valued at $1,410,000 after buying an additional 14,185 shares in the last quarter. Boothbay Fund Management LLC lifted its position in shares of Lexeo Therapeutics by 37.5% in the fourth quarter. Boothbay Fund Management LLC now owns 147,807 shares of the company’s stock worth $973,000 after purchasing an additional 40,323 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $69,000. Altium Capital Management LLC bought a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $2,665,000. Finally, Marshall Wace LLP bought a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $117,000. Institutional investors own 60.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on LXEO shares. Royal Bank of Canada restated an “outperform” rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, January 21st. Leerink Partners decreased their price objective on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Wednesday, November 13th. HC Wainwright boosted their price objective on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, November 14th. Finally, Chardan Capital boosted their price objective on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $23.80.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.